mRNA Cancer Vaccines: Moderna and BioNTech's Race for a Personalized Cure
By Sanna the Weaver • Sat Feb 14 2026 • Health
The mRNA platform that produced COVID-19 vaccines in record time was always understood to be a general-purpose technology. Moderna and BioNTech spent years before the pandemic developing mRNA for therapeutic applications, including cancer, and the COVID experience dramatically accelerated the manufacturing, regulatory, and scientific infrastructure needed to translate that research into medicines. In 2026, the cancer vaccine promise is beginning to be fulfilled: personalized mRNA cancer vaccines, designed for each individual patient's tumor, are in late-stage clinical trials with results that oncologists describe as "genuinely exciting." How Personalized Cancer Vaccines Work Cancer cells accumulate mutations that normal cells do not have. Some of these mutations produce protein fragments — called neoantigens — that the immune system could recognize as foreign, if it could be taught to look for them. A personalized mRNA cancer vaccine sequences a patient's tumor DNA, identifies the unique neoantigens that their specific cancer expresses, and manufactures an mRNA sequence encoding those neoantigens. When injected, the vaccine teaches the patient's immune system to recognize and attack cells expressing those proteins — which means the cancer cells, specifically. The Melanoma Data The most advanced clinical results are in melanoma, where Moderna's mRNA-4157 (V940), combined with Merck's pembrolizumab (Keytruda), has shown a 49% reduction in the risk of recurrence or death compared to pembrolizumab alone in patients with Stage 3 or 4 melanoma following surgical resection. These results, published in 2023 and confirmed in longer follow-up reported in 2025, are driving an expansion into additional tumor types including non-small cell lung cancer, renal cell carcinoma, and colorectal cancer. Phase 3 trials in melanoma and lung cancer are expected to report top-line results in late 2026. "For the first time, we can imagine a cancer treatment that is as specific as the tumor it targets — because it is designed around that specific tumor." — Moderna Chief Medical Officer, February 2026 Manufacturing and the AI Acceleration Personalized cancer vaccines require manufacturing a unique mRNA sequence for each patient, typically within six to eight weeks of tumor biopsy. The manufacturing process has been streamlined by AI — algorithms that analyze tumor sequencing data and identify optimal neoantigen candidates, predict immune response probabilities, and optimize mRNA sequence design have reduced the time from biopsy to injection and lowered production costs. BioNTech estimates it can manufacture a personalized cancer vaccine for approximately $50,000 per patient — still expensive, but within range of existing cancer immunotherapy costs that have won insurance coverage.